U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H37FO7
Molecular Weight 504.5887
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BETAMETHASONE DIPROPIONATE

SMILES

CCC(=O)OCC(=O)[C@]1([C@@]([H])(C)C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@]3([C@]([H])(C[C@@]21C)O)F)OC(=O)CC

InChI

InChIKey=CIWBQSYVNNPZIQ-XYWKZLDCSA-N
InChI=1S/C28H37FO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1

HIDE SMILES / InChI

Molecular Formula C28H37FO7
Molecular Weight 504.5887
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections. Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.Betamethasone is used for: treating certain conditions associated with decreased adrenal gland function. It is used to treat severe inflammation caused by certain conditions, including severe asthma, severe allergies, rheumatoid arthritis, ulcerative colitis, certain blood disorders, lupus, multiple sclerosis, and certain eye and skin conditions.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.3 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Palliative
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
76.8 ng/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
67.6 ng/mL
6 mg single, intramuscular
dose: 6 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
101 ng/mL
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
796 ng × h/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
811 ng × h/mL
6 mg single, intramuscular
dose: 6 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
46.3 μg × min/mL
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.9 h
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
10.2 h
6 mg single, intramuscular
dose: 6 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
335 min
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
36%
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
7.2 mg 1 times / day multiple, oral
Highest studied dose
Dose: 7.2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 7.2 mg, 1 times / day
Sources:
unhealthy, adult
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
Simultaneous determination of betamethasone and dexamethasone residues in bovine liver by liquid chromatography/tandem mass spectrometry.
2001
Repeated ultrasound guided fetal injections of corticosteroid alter nervous system maturation in the ovine fetus.
2001
Infantile periocular haemangioma treated with two days in a week betamethasone oral mini pulse therapy.
2001 Apr
Orbital mass following injection with depot corticosteroids.
2001 Apr
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures.
2001 Apr
Antenatal betamethasone administration decreases the lung hyaluronan concentration in preterm rabbit pups.
2001 Apr
Determination of apparent association constants of steroid-cyclodextrin inclusion complexes using a modification of the Hummel-Dreyer method.
2001 Apr 13
Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret.
2001 Apr 13
Accelerated solvent extraction and liquid chromatography-tandem mass spectrometry quantitation of corticosteroid residues in bovine liver.
2001 Apr 5
A topical steroid without an antibiotic cures external otitis efficiently: a study in an animal model.
2001 Aug
Single versus repeated-course antenatal corticosteroids: outcomes in singleton and multiple-gestation pregnancies.
2001 Aug
Infantile acute hemorrhagic edema of the skin.
2001 Aug
Evaluation of the inhibitory activity of topical indomethacin, betamethasone valerate and emollients on UVL-induced inflammation by means of non-invasive measurements of the skin elasticity.
2001 Aug
Lichen planus-like eruption following autologous bone marrow transplantation for chronic myeloid leukaemia.
2001 Aug
Repeated prenatal corticosteroid administration delays astrocyte and capillary tight junction maturation in fetal sheep.
2001 Aug
Placebo-controlled, blinded comparison of antenatal betamethasone on mouse liver development.
2001 Feb
Betamethasone alteration of the one-hour glucose challenge test in pregnancy.
2001 Feb
Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506).
2001 Feb
Repeated courses of antenatal corticosteroids.
2001 Feb
Repeated fetal betamethasone treatment and birth weight and head circumference.
2001 Feb
Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp.
2001 Jan
Topical therapy with fluorinated and non-fluorinated corticosteroids in patients with atopic dermatitis.
2001 Jan
The effect of multidose antenatal betamethasone on maternal and infant outcomes.
2001 Jan
Antenatal steroids and neonatal periventricular leukomalacia.
2001 Jan
Surfactant levels after reversible tracheal occlusion and prenatal steroids in experimental diaphragmatic hernia.
2001 Jan
Severe vulvovaginitis associated with intravaginal nystatin therapy.
2001 Jul
The interactive effects of endotoxin with prenatal glucocorticoids on short-term lung function in sheep.
2001 Jul
An evidence-based assessment of occlusal adjustment as a treatment for temporomandibular disorders.
2001 Jul
Inflammatory pathological changes in a 2-year-old boy with Charcot-Marie-Tooth disease.
2001 Jul
Tocolytic magnesium sulfate toxicity and unexpected neonatal death.
2001 Jun
Treatment of de Quervain's disease:role of conservative management.
2001 Jun
Indomethacin tocolysis and intraventricular hemorrhage.
2001 Jun
Allergic contact dermatitis from betamethasone valerate in Japan.
2001 Mar
Therapeutic zygapophyseal joint injections for headaches emanating from the C2-3 joint.
2001 Mar
Increase in prostaglandin H synthase 2, but not prostaglandin F2alpha synthase mRNA in intrauterine tissues during betamethasone-induced premature labor and spontaneous term labor in sheep.
2001 Mar-Apr
Femoral head osteonecrosis after topical corticosteroid therapy.
2001 Mar-Apr
Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI.
2001 May
Lung morphometry after repetitive antenatal glucocorticoid treatment in preterm sheep.
2001 May
High injection pressure during intralesional injection of corticosteroids into capillary hemangiomas.
2001 May
Pulmonary structural maturation and pulmonary artery remodeling after reversible fetal ovine tracheal occlusion in diaphragmatic hernia.
2001 May
Repeated antenatal glucocorticoid treatment decreases hypothalamic corticotropin releasing hormone mRNA but not corticosteroid receptor mRNA expression in the fetal guinea-pig brain.
2001 May
Lumbar facet joint synovial cyst: percutaneous treatment with steroid injections and distention--clinical and imaging follow-up in 12 patients.
2001 Oct
Use of antenatal steroids to counteract the negative effects of tracheal occlusion in the fetal lamb model.
2001 Oct
Multiple courses of antenatal steroids: risks and benefits.
2001 Sep
Fetal monkey surfactants after intra-amniotic or maternal administration of betamethasone and thyroid hormone.
2001 Sep
Treatment of childhood phimosis with a moderately potent topical steroid.
2001 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Can also be used topically https://medlineplus.gov/druginfo/meds/a682799.html
The initial dosage of parenterally administered Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may vary from 0.25 to 9 mg per day depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administrations in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. In the treatment of acute exacerbations of multiple sclerosis, daily doses of 30 mg of betamethasone for a week followed by 12 mg every other day for 1 month are recommended.In pediatric patients, the initial dose of betamethasone may vary depending on the specific disease entity being treated. The range of initial doses is 0.02 to 0.3 mg/kg/day in three or four divided doses (0.6 to 9 mg/m2bsa/day).
Route of Administration: Parenteral
In Vitro Use Guide
Betamethasone (10(-6)M) significantly reduced both pH 6-induced bronchial response and CGRP-like immunoreactivity overflow in guinea-pig isolated perfused lung.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:17:54 UTC 2021
Edited
by admin
on Fri Jun 25 21:17:54 UTC 2021
Record UNII
826Y60901U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BETAMETHASONE DIPROPIONATE
EP   GREEN BOOK   MART.   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
LEO-90100 COMPONENT BETAMETHASONE DIPROPIONATE
Common Name English
BETAMETHASONE DIPROPIONATE [WHO-DD]
Common Name English
NSC-758415
Code English
DIPROSPAN
Common Name English
ALPHATREX
Brand Name English
TACLONEX COMPONENT BETAMETHASONE DIPROPIONATE
Common Name English
BETAMETHASONE DIPROPIONATE [GREEN BOOK]
Common Name English
BETAMETHASONE DIPROPIONATE COMPONENT OF ENSTILAR
Brand Name English
BETAMETHASONE 17.ALPHA.,21-DIPROPIONATE
Common Name English
BETAMETHASONE DIPROPIONATE, AUGMENTED
Common Name English
BETAMETHASONE DIPROPIONATE [MART.]
Common Name English
DIPROSONE
Brand Name English
LOTRISONE COMPONENT BETAMETHASONE DIPROPIONATE
Common Name English
BETAMETHASONE DIPROPIONATE COMPONENT OF LOTRISONE
Common Name English
BETAMETHASONE DIPROPIONATE [EP MONOGRAPH]
Common Name English
PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11-HYDROXY-16-METHYL-17,21-BIS(1-OXOPROPOXY)-, (11.BETA.,16.BETA.)
Common Name English
BETAMETHASONE DIPROPIONATE COMPONENT OF LEO-90100
Common Name English
ENSTILAR COMPONENT BETAMETHASONE DIPROPIONATE
Brand Name English
MAXIVATE
Common Name English
BETAMETHASONE (AS DIPROPIONATE)
Common Name English
DIPROLENE
Brand Name English
BETAMETHASONE DIPROPIONATE COMPONENT OF WYNZORA
Brand Name English
BETAMETHASONE DIPROPIONATE [USP-RS]
Common Name English
.BETA.-METHASONE 17,21-DIPROPIONATE
Common Name English
BETAMETHASONE DIPROPIONATE COMPONENT OF TACLONEX
Common Name English
RINDERON DP
Common Name English
SCH-11460
Code English
BETAMETHASONE DIPROPIONATE [VANDF]
Common Name English
BETAMETHASONE 17,21-DIPROPIONATE [MI]
Common Name English
BETAMETHASONE DIPROPIONATE [USP]
Common Name English
BETAMETHASONE DIPROPIONATE [JAN]
Common Name English
PSORION
Common Name English
WYNZORA COMPONENT BETAMETHASONE DIPROPIONATE
Brand Name English
BETAMETHASONE DIPROPIONATE [USAN]
Common Name English
SCH 11460
Code English
9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.BETA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE 17,21-DIPROPIONATE
Common Name English
BETAMETHASONE DIPROPIONATE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 522.163
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
NCI_THESAURUS C521
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
Code System Code Type Description
PUBCHEM
21800
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
EVMPD
SUB00783MIG
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
RXCUI
215664
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
ALTERNATIVE
DRUG BANK
DBSALT000851
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
MERCK INDEX
M2452
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
BETAMETHASONE DIPROPIONATE
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
USP_CATALOG
1067704
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY USP-RS
CAS
5593-20-4
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
EPA CompTox
5593-20-4
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
NCI_THESAURUS
C47963
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
RXCUI
19254
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
ChEMBL
CHEMBL1200384
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
ECHA (EC/EINECS)
227-005-2
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
DRUG CENTRAL
353
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
FDA UNII
826Y60901U
Created by admin on Fri Jun 25 21:17:54 UTC 2021 , Edited by admin on Fri Jun 25 21:17:54 UTC 2021
PRIMARY
Related Record Type Details
DERIVATIVE -> PARENT
DEGRADENT -> PARENT
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
http://apps.who.int/phint/pdf/b/Jb.6.1.43.pdf
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY